132.59
Biogen Inc stock is traded at $132.59, with a volume of 1.23M.
It is up +1.23% in the last 24 hours and up +4.97% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$130.98
Open:
$130.78
24h Volume:
1.23M
Relative Volume:
0.85
Market Cap:
$19.43B
Revenue:
$9.82B
Net Income/Loss:
$1.48B
P/E Ratio:
13.09
EPS:
10.13
Net Cash Flow:
$2.30B
1W Performance:
+3.03%
1M Performance:
+4.97%
6M Performance:
-9.31%
1Y Performance:
-41.34%
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BIIB
Biogen Inc
|
132.59 | 19.19B | 9.82B | 1.48B | 2.30B | 10.13 |
![]()
LLY
Lilly Eli Co
|
805.43 | 717.19B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
169.56 | 404.05B | 90.63B | 22.66B | 18.57B | 9.35 |
![]()
ABBV
Abbvie Inc
|
190.83 | 330.51B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
117.46 | 228.37B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
NVO
Novo Nordisk Adr
|
70.73 | 311.17B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-21-25 | Resumed | Truist | Hold |
Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
Apr-04-25 | Downgrade | Argus | Buy → Hold |
Feb-11-25 | Initiated | Bernstein | Mkt Perform |
Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-16-24 | Downgrade | Stifel | Buy → Hold |
Dec-10-24 | Resumed | BofA Securities | Neutral |
Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
Nov-18-24 | Downgrade | Needham | Buy → Hold |
Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
Nov-14-24 | Initiated | Citigroup | Neutral |
Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Feb-14-24 | Reiterated | Needham | Buy |
Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jan-24-24 | Downgrade | UBS | Buy → Neutral |
Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Sep-06-23 | Initiated | HSBC Securities | Buy |
Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
Jul-24-23 | Reiterated | UBS | Buy |
May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
Oct-13-22 | Upgrade | Stifel | Hold → Buy |
Oct-07-22 | Upgrade | Argus | Hold → Buy |
Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-08-22 | Downgrade | Stifel | Buy → Hold |
Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Feb-04-22 | Reiterated | Barclays | Equal Weight |
Feb-04-22 | Reiterated | BofA Securities | Neutral |
Feb-04-22 | Reiterated | Cowen | Outperform |
Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
Feb-04-22 | Reiterated | Needham | Buy |
Feb-04-22 | Reiterated | Oppenheimer | Outperform |
Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
Feb-04-22 | Reiterated | Wedbush | Neutral |
Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-10-21 | Resumed | Raymond James | Mkt Perform |
Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
Dec-06-21 | Initiated | Goldman | Neutral |
Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
Sep-23-21 | Initiated | Needham | Buy |
Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Jun-14-21 | Reiterated | Truist | Buy |
Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
Jun-10-21 | Upgrade | UBS | Neutral → Buy |
Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
Jun-08-21 | Reiterated | Barclays | Equal Weight |
Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
Jun-08-21 | Reiterated | Jefferies | Buy |
Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
Jun-08-21 | Reiterated | Stifel | Buy |
Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
Jan-29-21 | Upgrade | Stifel | Hold → Buy |
Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-28-20 | Initiated | UBS | Neutral |
Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
Feb-27-20 | Initiated | Barclays | Overweight |
Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Is Biogen Inc. a good long term investmentFree Buy/Sell Signal Notifications - PrintWeekIndia
Genentech Seeks Win After $122M Biogen Royalties Mistrial - Law360
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Recipients - TipRanks
Biogen, Zydus Settle Patent Suit Over Copies of MS Drug Vumerity - Bloomberg Law News
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Has $21.55 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional
Biogen to invest $2 billion in RTP, open new factory in 2025 - WRAL.com
(BIIB) On The My Stocks Page - news.stocktradersdaily.com
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Rep. Robert Bresnahan, Jr. Buys Biogen Inc. (NASDAQ:BIIB) Shares - MarketBeat
How the Recombinant Dna Technology Market Will Evolve by 2032 - openPR.com
KLP Kapitalforvaltning AS Purchases 63,700 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Envestnet Asset Management Inc. Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stake Raised by Victory Capital Management Inc. - MarketBeat
Will Major North Carolina Expansion Change Biogen's (BIIB) Narrative? - simplywall.st
Beacon Investment Advisory Services Inc. Sells 3,529 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Benzinga
Biogen, one of the largest employers in RTP, plans $2B investment in the Triangle - Axios
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - The Globe and Mail
Allianz Asset Management GmbH Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Los Angeles Capital Management LLC Takes $5.93 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Spinal Muscular Atrophy Treatment Market Growth Accelerated - openPR.com
What drives Biogen Inc. stock pricePowerful growth strategies - jammulinksnews.com
Biogen: Hold Rating Amid Stagnant Growth and Uncertain Prospects - TipRanks
Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN
Biogen to invest further $2bn in North Carolina’s Research Triangle Park - Yahoo Finance
Iovance Biotherapeutics shares rise 2.41% premarket after Biogen's $2 billion investment in North Carolina manufacturing. - AInvest
What analysts say about Biogen Inc. stockFree Predictions - jammulinksnews.com
Biogen investing $2B to expand operations in RTP - ABC11
Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth - AInvest
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - yahoo.co
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - Biogen
Biogen Breakthrough: 48-Month LEQEMBI Results Plus Game-Changing Subcutaneous Alzheimer's Treatment Option - Stock Titan
Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to invest $2 billion in RTP facility - CBS 17
Biogen Inc. Invests $2B In North Carolina Expansion - Business Facilities
Biogen Inc. Announces $2 Billion Expansion in North Carolina's Research Triangle Park Amid U.S. Manufacturing Push - Hoodline
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance
Biogen Bets Big On $2 Billion Expansion To Boost US Drug ManufacturingBiogen (NASDAQ:BIIB) - Benzinga
Biogen invests $2B in U.S. manufacturing — but not in Massachusetts - The Business Journals
Biogen to invest $2 billion in Research Triangle Park facilities - CBS 17
Biogen’s Pediatric RRMS Study Completion: Market Implications and Insights - TipRanks
Biogen (NASDAQ:BIIB) Coverage Initiated by Analysts at Truist Financial - MarketBeat
Biogen Invests $20 Billion in North Carolina to Counter 200% Tariff Threat - AInvest
Biogen to invest further $2 billion in North Carolina facilities - The Pharma Letter
Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm - Reuters
Drugmaker Biogen to invest $2 billion more in North Carolina - 104.1 WIKY
Truist downgrades Biogen, citing growth challenges, limited pipeline upside - TradingView
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):